Literature DB >> 7529046

The two genes generating RET/PTC3 are localized in chromosomal band 10q11.2.

F Minoletti1, M G Butti, S Coronelli, M Miozzo, G Sozzi, S Pilotti, A Tunnacliffe, M A Pierotti, I Bongarzone.   

Abstract

PCR analysis of DNA from a selected panel of human-rodent somatic cell hybrids and fluorescent in situ hybridization (FISH) analysis allowed us to localize the human ELE1 gene. This previously uncharacterized gene is fused with the tyrosine kinase (tk) domain of the RET proto-oncogene to generate the oncogenic sequence RET/PTC3, thus providing a third example of RET oncogenic activation in papillary thyroid carcinomas. ELE1 was localized to band 10q11.2, the subband where RET also maps, at a minimum distance of more than 500 kb from the proto-oncogene. The fusion event corresponding to the rearrangement reciprocal to that leading to the formation of RET/PTC3 was also identified and characterized. The karyotype of two RET/PTC3 positive tumors did not show any evidence of chromosome 10 abnormalities. The data indicate that a cytogenetically undetectable paracentric inversion within 10q11.2 generates RET/PTC3.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7529046     DOI: 10.1002/gcc.2870110108

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  10 in total

Review 1.  The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 2.  The RET proto-oncogene: a challenge to our understanding of disease pathogenesis.

Authors:  T Kusafuka; P Puri
Journal:  Pediatr Surg Int       Date:  1997       Impact factor: 1.827

Review 3.  Mouse models of endocrine tumours.

Authors:  Georgette N Jones; Parmeet K Manchanda; Daphne R Pringle; Mei Zhang; Lawrence S Kirschner
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

Review 4.  Molecular genetics and diagnosis of thyroid cancer.

Authors:  Yuri E Nikiforov; Marina N Nikiforova
Journal:  Nat Rev Endocrinol       Date:  2011-08-30       Impact factor: 43.330

5.  Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.

Authors:  Raffaele Ciampi; Jeffrey A Knauf; Roswitha Kerler; Manoj Gandhi; Zhaowen Zhu; Marina N Nikiforova; Hartmut M Rabes; James A Fagin; Yuri E Nikiforov
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

Review 6.  RET/PTC rearrangement in thyroid tumors.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

7.  The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain.

Authors:  A Greco; C Mariani; C Miranda; A Lupas; S Pagliardini; M Pomati; M A Pierotti
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272

8.  Correlation of MLH1 and MGMT expression and promoter methylation with genomic instability in patients with thyroid carcinoma.

Authors:  Juliana Carvalho Santos; André Uchimura Bastos; Janete Maria Cerutti; Marcelo Lima Ribeiro
Journal:  BMC Cancer       Date:  2013-02-15       Impact factor: 4.430

9.  Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma.

Authors:  Elisa Menicali; Sonia Moretti; Pasquale Voce; Serena Romagnoli; Nicola Avenia; Efisio Puxeddu
Journal:  Front Endocrinol (Lausanne)       Date:  2012-05-22       Impact factor: 5.555

Review 10.  Selective use of sorafenib in the treatment of thyroid cancer.

Authors:  Fabián Pitoia; Fernando Jerkovich
Journal:  Drug Des Devel Ther       Date:  2016-03-11       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.